NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Reviewed May 26, 2026

Thymosin Alpha-1

Peptide ·Moderate evidence ·Reviewed May 2026

Thymosin Alpha-1 is a 28-amino-acid thymic peptide that modulates innate and adaptive immune responses. It is approved in some countries for hepatitis B or immune-adjuvant uses, but it is not FDA-approved in the United States. Evidence is strongest in selected infectious, sepsis, and hepatitis research settings, not general immune boosting.

What it's good for
  • Approved outside the US for selected immune indications2,3
  • Studied as an adjunct in hepatitis and sepsis3,1
  • Can modulate T-cell and dendritic-cell function
  • Not FDA-approved in the US
What to watch for
  • Injection-site reaction
  • Fatigue
  • Headache
  • Pregnancy and breastfeeding unless specialist-directed
  • Autoimmune disease flare without specialist review

The bottom line

Evidence rating moderate. Most-documented uses: approved outside the us for selected immune indications, studied as an adjunct in hepatitis and sepsis, can modulate t-cell and dendritic-cell function. 3 sources indexed (2015–2020), with 3 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Thymosin alpha-1 influences dendritic-cell maturation, T-cell differentiation, NK-cell activity, antigen presentation, and cytokine balance through pathways that include TLR and interferon-related signaling. It tends to normalize dysregulated immunity rather than simply stimulate it, but clinical effects vary by disease state. Use with autoimmune disease, transplant immunosuppression, chemotherapy, or biologics requires specialist review.1,2

Class
Thymic immunomodulatory peptide
Found in food
None as a dietary supplement
Low-status signs
No recognized dietary deficiency state exists for this peptide
Dosing

Dosing & protocol.

Common range
No FDA-approved US dose; approved-country protocols commonly use clinician-directed subcutaneous dosing such as 1.6 mg twice weekly for selected indications
Recommended form
Regulated prescription product where approved; avoid research-grade peptides

Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.

Forms

Forms & what to buy.

Ranked by evidence and value.

Regulated Thymalfasin Injection Recommended
Subcutaneous route with known pharmaceutical quality where approved. Use only under clinician supervision.
PremiumClinician-directed
Compounded Thymosin Alpha-1
Not an FDA-approved finished product in the US. Quality depends on pharmacy controls.
PremiumClinician-directed only
Research Peptide Vial
Not appropriate for human injection. Sterility and identity cannot be trusted.
PremiumNo human dose
Cost

What it actually costs.

Real-world pricing across three quality tiers. Assumes Regulated Thymalfasin Injection.

BudgetBest value
$60 /mo
$2.00 per dose
Mid
$180 /mo
$6.00 per dose
Premium
$450 /mo
$15.00 per dose

Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.

Goals

Goal-based dosing.

Chronic Hepatitis Research

Dose: Clinician-directed protocols only3

Timing: Per specialist protocol

Do not replace antiviral therapy.

Sepsis or Critical Illness Adjunct Research

Dose: Hospital protocol only1

Timing: Specialist-directed

Not for outpatient self-use.

Immune Support Wellness

Dose: No FDA-approved US dose2,3

Timing: Not applicable

General immune boosting is not an established indication.

Lab work

Markers to track.

What to test, the optimal window inside the conventional range, and how long a response takes.

Absolute Lymphocyte Count ALC

May be followed in immune-compromised contexts but is not a specific response marker.2,3

Optimal
1200–3500 cells/uL
Conventional
1000–4800 cells/uL
Responds in
Baseline and follow-up per clinician

Interpret with CBC differential and clinical context.

CBC with differentialCD4 count

CD4 T-Cell Count CD4

Relevant in selected immune monitoring contexts.2,3

Optimal
500–1200 cells/uL
Conventional
500–1500 cells/uL
Responds in
Per specialist plan

Do not self-interpret for immune treatment decisions.

CD8 countCD4/CD8 ratio
Why people use it

Symptoms it's matched to.

Where this appears in the symptom-to-supplement map, ranked by relevance.

Immune suppression

20% relevance

Studied as adjunct in some immune-compromised and infection contexts.3,2

ImmuneEmerging evidenceSpecialist-directed only

Coordinate with oncology, infectious disease, or transplant teams.

Frequent infections

18% relevance

Immunomodulatory research may be relevant in selected diagnosed immune dysfunction, not routine colds.1,2

ImmuneEmerging evidenceSpecialist-directed prescription product

Evaluate immunoglobulins, CBC, and exposures.

Slow recovery from infection

10% relevance

Evidence is disease-specific and not a general recovery enhancer.

ImmuneInsufficient evidenceAvoid self-use

Persistent infection symptoms need medical care.

Safety

Full safety detail.

Side effects

  • Injection-site reaction
  • Fatigue
  • Headache
  • Nausea
  • Flu-like symptoms
  • Rash
  • Potential immune flare in susceptible patients

Contraindications

  • Pregnancy and breastfeeding unless specialist-directed
  • Autoimmune disease flare without specialist review
  • Solid-organ transplant or immunosuppressive therapy without transplant-team approval
  • Active malignancy without oncology coordination
  • Use of research-grade injectable products
Interactions

Interaction records.

ModerateCaution

Ashwagandha

Ashwagandha has immune and thyroid effects and could complicate autoimmune or immune-modulating protocols.

Recommendation: Avoid combining in autoimmune disease or immunosuppression unless a clinician approves.

InfoSynergy

Zinc

Zinc deficiency can impair immune function, but high-dose zinc can cause copper deficiency.

Recommendation: Correct deficiency through standard dosing; avoid megadoses.

InfoSynergy

Vitamin D3

Vitamin D status is relevant to immune regulation but does not replace immunologic diagnosis.

Recommendation: Check and correct deficiency if clinically indicated.

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

1
  • 1The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trialsNeeds sourceNo linkWu J et al. · Critical Care · 2016

    Mortality signal favored thymosin alpha-1

Reviews & position papers

2
  • 2Thymosin alpha 1: A comprehensive review of the literatureNeeds sourceNo linkKing R et al. · World Journal of Virology · 2020

    Multiple immune indications reviewed

  • 3Thymosin alpha-1 treatment in chronic hepatitis BNeeds sourceNo linkZhao Y et al. · Expert Opinion on Biological Therapy · 2015

    Immune-adjuvant role reviewed

Keep exploring

Deep dives & adjacent profiles.

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

Thymosin Alpha-1 in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.